RAPT Therapeutics RAPT

$ 1.07 1.43%

Quarterly report 2024-Q3
added 11-12-2024

RAPT Therapeutics Balance Sheet 2011-2024 | RAPT

Annual Balance Sheet RAPT Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-40.6 M	-30 M	-	-24.9 M	-77.4 M	-63.8 M	-47.5 M	-	-	-	-	-	-
Long Term Debt	4.46 M	6.82 M	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.45 M	2.17 M	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	2.22 M	969 K	110 M	-	-	-	-	-	-
Total Current Liabilities	21.8 M	14.2 M	9.6 M	11.7 M	9.26 M	-	-	-	-	-	-	-	-
Total Liabilities	26.3 M	21 M	12.3 M	14.8 M	11.5 M	5.61 M	113 M	-	-	-	-	-	-
Deferred Revenue	-	-	1.02 M	4.1 M	4 M	-	-	-	-	-	-	-	-
Retained Earnings	-485 M	-368 M	-284 M	-	-162 M	-119 M	-82.8 M	-	-	-	-	-	-
Total Assets	173 M	266 M	199 M	119 M	84.6 M	69.6 M	50.4 M	-	-	-	-	-	-
Cash and Cash Equivalents	47.5 M	38.9 M	24 M	24.9 M	77.4 M	-	-	-	-	-	-	-	-
Book Value	147 M	245 M	186 M	104 M	73.1 M	64 M	-62.4 M	-	-	-	-	-	-
Total Shareholders Equity	147 M	245 M	186 M	104 M	73.1 M	-97.1 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet RAPT Therapeutics

	2024-Q3	2024-Q2	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	2.6 M	3.16 M	5.07 M	5.66 M	6.25 M	6.82 M	6.32 M	6.72 M	7.11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	13 M	18 M	26.9 M	21.1 M	27.9 M	21 M	20.2 M	19.9 M	19.7 M	12.3 M	15.6 M	13.5 M	14.3 M	14.8 M	14.8 M	14.8 M	14.8 M	11.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	645 K	1.02 M	1.54 M	2.28 M	3.14 M	4.1 M	4.1 M	4.1 M	4.1 M	4 M	4 M	4 M	4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-561 M	-543 M	-454 M	-422 M	-397 M	-368 M	-345 M	-324 M	-305 M	-284 M	-266 M	-247 M	-231 M	-215 M	-215 M	-215 M	-215 M	-162 M	-162 M	-162 M	-162 M	-119 M	-119 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	108 M	127 M	200 M	221 M	248 M	266 M	209 M	222 M	188 M	199 M	217 M	231 M	106 M	119 M	119 M	119 M	119 M	84.6 M	84.6 M	84.6 M	84.6 M	69.6 M	69.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	37.9 M	37.1 M	54.1 M	50.2 M	45.8 M	38.9 M	27.7 M	57.2 M	32.4 M	24 M	60 M	86.2 M	24.7 M	24.9 M	24.9 M	24.9 M	24.9 M	77.4 M	77.4 M	77.4 M	77.4 M	63.8 M	63.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	95.5 M	109 M	173 M	200 M	220 M	245 M	189 M	202 M	168 M	186 M	202 M	218 M	91.6 M	104 M	104 M	104 M	104 M	73.1 M	84.6 M	84.6 M	84.6 M	69.6 M	69.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	95.5 M	109 M	173 M	200 M	220 M	245 M	189 M	202 M	168 M	186 M	202 M	218 M	91.6 M	104 M	104 M	104 M	104 M	73.1 M	73.1 M	73.1 M	73.1 M	-97.1 M	-97.1 M	-78.1 M	-70.2 M	-62.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency